SCHEMBL2845648

SCHEMBL2845648

CC[Si](CC)(CC)OC(C)(C)CCCCC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.42
GPR84 Q9NQS5 7/20 0.41
PPARG P37231 7/20 0.41
PPARD Q03181 7/20 0.41
PPARA Q07869 7/20 0.41
HDAC11 Q96DB2 5/20 0.41
TSHR P16473 5/20 0.41
PTPN1 P18031 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TLR2 O60603 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
FABP4 P15090 2/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
MEN1 O00255 1/20 0.41
ESR1 P03372 1/20 0.41
ALOX15 P16050 1/20 0.41
PDE4A P27815 1/20 0.41
KMT2A Q03164 1/20 0.41
PDE3A Q14432 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3183846 0.95 AKR1B1 (0.39) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL2851193 0.87 ALDH1A1 (0.38) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL2843514 0.77 AKR1B1 (0.36) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL3184777 0.75 AKR1B1 (0.38) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL157395 0.75 ALDH1A1 (0.48) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL3184614 0.75 AKR1B1 (0.34) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL986920 0.73 ALDH1A1 (0.52) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL21560955 0.73 AKR1B1 (0.43) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL21560981 0.72 LMNA (0.44) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL12329361 0.71 GPR84 (0.45) AKR1B1GPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2025667-B1 9,10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL NIPPON SHINYAKU CO LTD (JP) 2016-08-10 EP disclosed
US-8796246-B2 9, 10-secopregnane derivative and pharmaceutical NIPPON SHINYAKU CO., LTD. (JP) 2014-08-05 US disclosed
US-20100130454-A1 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE NIPPON SHINYAKU CO., LTD. (JP) 2010-05-27 US disclosed
US-20100016263-A1 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2010-01-21 US disclosed
EP-2025667-A1 9,10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL Nippon Shinyaku Co., Ltd. (JP) 2009-02-18 EP disclosed
EP-1829860-A1 9,10-SECOPREGNANE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2007-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130454-A1 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE VDR, CYP2R1, CYP24A1 AKR1B1 484/4885GPR84 95/4885PPARG 250/4885
US-20100016263-A1 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL CYP2R1, VDR, CYP24A1 AKR1B1 427/4885GPR84 148/4885PPARG 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.